Why did European Radiology reject my radiomic biomarker paper? How to correctly evaluate imaging biomarkers in a clinical setting

被引：36

作者：

Halligan, Steve ^{[1
]}

Menu, Yves ^{[2
]}

Mallett, Sue ^{[1
]}

机构：

[1] Univ Coll London UCL, Ctr Med Imaging, 43-45 Foley St, London W1W 7TS, England

[2] Sorbonne Univ, St Antoine Hosp, AP HP, Dept Diagnost & Intervent Radiol, Paris, France

来源：

EUROPEAN RADIOLOGY | 2021年 / 31卷 / 12期

关键词：

Research design; Biomarkers; Publications; Radiomics; Peer review; PROGNOSTIC MODELS; EXTERNAL VALIDATION; PREDICTION MODELS; CANCER; IMPACT; RISK; DIAGNOSIS; DISEASE; EVENTS;

D O I：

10.1007/s00330-021-07971-1

中图分类号：

R8 [特种医学]; R445 [影像诊断学];

学科分类号：

1002 ; 100207 ; 1009 ;

摘要：

This review explains in simple terms, accessible to the non-statistician, general principles regarding the correct research methods to develop and then evaluate imaging biomarkers in a clinical setting, including radiomic biomarkers. The distinction between diagnostic and prognostic biomarkers is made and emphasis placed on the need to assess clinical utility within the context of a multivariable model. Such models should not be restricted to imaging biomarkers and must include relevant disease and patient characteristics likely to be clinically useful. Biomarker utility is based on whether its addition to the basic clinical model improves diagnosis or prediction. Approaches to both model development and evaluation are explained and the need for adequate amounts of representative data stressed so as to avoid underpowering and overfitting. Advice is provided regarding how to report the research correctly.

引用

页码：9361 / 9368

页数：8

共 57 条

[1] Validation and Utility Testing of Clinical Prediction Models Time to Change the Approach
Adibi, Amin
Sadatsafavi, Mohsen
Ioannidis, John P. A.
[J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2020, 324 (03): : 235 - 236
[2] Altman DG, 2000, STAT MED, V19, P453, DOI 10.1002/(SICI)1097-0258(20000229)19:4<453::AID-SIM350>3.3.CO
[3] 2-X
[4] Prognosis and prognostic research: validating a prognostic model
Altman, Douglas G.
Vergouwe, Yvonne
Royston, Patrick
Moons, Karel G. M.
[J]. BMJ-BRITISH MEDICAL JOURNAL, 2009, 338 : 1432 - 1435
[5] Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework
Atkinson, AJ
Colburn, WA
DeGruttola, VG
DeMets, DL
Downing, GJ
Hoth, DF
Oates, JA
Peck, CC
Schooley, RT
Spilker, BA
Woodcock, J
Zeger, SL
[J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2001, 69 (03) : 89 - 95
[6] Biomarker: Predictive or Prognostic?
Ballman, Karla V.
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (33) : 3968 - +
[7] Guide to presenting clinical prediction models for use in clinical settings
Bonnett, Laura J.
Snell, Kym I. E.
Collins, Gary S.
Riley, Richard D.
[J]. BMJ-BRITISH MEDICAL JOURNAL, 2019, 365
[8] False Discovery Rates in PET and CT Studies with Texture Features: A Systematic Review
Chalkidou, Anastasia
O'Doherty, Michael J.
Marsden, Paul K.
[J]. PLOS ONE, 2015, 10 (05):
[9] Collins GS, 2015, ANN INTERN MED, V162, P55, DOI [10.7326/M14-0697, 10.1016/j.jclinepi.2014.11.010, 10.1186/s12916-014-0241-z, 10.1038/bjc.2014.639, 10.7326/M14-0698, 10.1002/bjs.9736, 10.1136/bmj.g7594, 10.1016/j.eururo.2014.11.025]
[10] Development and validation of a MRI-based radiomics signature for prediction of KRAS mutation in rectal cancer
Cui, Yanfen
Liu, Huanhuan
Ren, Jialiang
Du, Xiaosong
Xin, Lei
Li, Dandan
Yang, Xiaotang
Wang, Dengbin
[J]. EUROPEAN RADIOLOGY, 2020, 30 (04) : 1948 - 1958

← 1 2 3 4 5 6 →